Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 527	$ 2,352
Accounts and grants receivable, net	326	363
Prepaid expenses and other current assets	1,430	1,339
Total current assets	2,283	4,054
Property and equipment, net		1,126
Deposits and other long-term assets	50	111
Intangible assets, net	1,592	2,151
TOTAL ASSETS	3,925	7,442
CURRENT LIABILITIES
Accounts payable and accrued liabilities	1,656	1,582
Loan due to Juvenescence, net of debt issuance cost, current portion	1,960
Related party payables, net	71	64
Deferred revenues, current portion	275	283
Right-of-use lease liability		428
Paycheck Protection Program Loan	436
Insurance premium liability and other current liabilities	959	940
Total current liabilities	5,357	3,297
Loan due to Juvenescence, net of debt issuance cost, net of current portion	3,900	1,528
Deferred revenues, net of current portion	64
TOTAL LIABILITIES	9,321	4,825
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of December 31, 2020 and 2019
Common stock, $0.0001 par value, 100,000 shares authorized; 37,691 and 37,649 shares issued and outstanding as of December 31, 2020 and 2019, respectively	4	4
Additional paid-in capital	91,810	88,353
Accumulated other comprehensive income	143	69
Accumulated deficit	(97,073)	(86,208)
AgeX Therapeutics, Inc. stockholders' equity (deficit)	(5,116)	2,218
Noncontrolling interest	(280)	399
Total stockholders' equity (deficit)	(5,396)	2,617
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 3,925	$ 7,442